Analysts expect that NewLink Genetics Corporation (NASDAQ:NLNK) will report $2.38 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for NewLink Genetics Corporation’s earnings, with the highest sales estimate coming in at $5.00 million and the lowest estimate coming in at $300,000.00. NewLink Genetics Corporation posted sales of $15.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 84.5%. The firm is expected to announce its next earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that NewLink Genetics Corporation will report full year sales of $2.38 million for the current fiscal year, with estimates ranging from $13.13 million to $23.10 million. For the next fiscal year, analysts expect that the business will post sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for NewLink Genetics Corporation.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. The firm had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%.

NLNK has been the topic of several recent research reports. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corporation and gave the stock a “buy” rating in a research report on Thursday, May 4th. Robert W. Baird reiterated an “outperform” rating and issued a $25.00 price objective on shares of NewLink Genetics Corporation in a research report on Monday, June 5th. ValuEngine upgraded NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research report on Friday, May 19th. Zacks Investment Research downgraded NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $18.00 price objective on shares of NewLink Genetics Corporation in a research report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $18.17.

Several large investors have recently modified their holdings of the company. Columbus Circle Investors increased its stake in shares of NewLink Genetics Corporation by 72.5% in the second quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock worth $4,349,000 after buying an additional 248,724 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $5,127,000. EAM Investors LLC acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $4,622,000. Ameriprise Financial Inc. acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $3,453,000. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $2,578,000. Institutional investors own 51.48% of the company’s stock.

NewLink Genetics Corporation (NASDAQ NLNK) opened at 6.53 on Friday. The firm has a 50-day moving average price of $7.31 and a 200 day moving average price of $13.61. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The firm’s market capitalization is $192.12 million.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate NewLink Genetics Corporation (NASDAQ:NLNK) Will Announce Quarterly Sales of $2.38 Million” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/analysts-anticipate-newlink-genetics-corporation-nasdaqnlnk-will-announce-quarterly-sales-of-2-38-million/1471953.html.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.